Tetra Therapeutics
Dr. Richard Nugent leads programs for the CNS application of PDE4 inhibitors for Tetra. Prior to this work, he worked on projects aimed at treating cystic fibrosis for Flatley Discovery Labs and drug discovery projects against inflammation, osteoporosis, and metabolic diseases as well as anti-infectives and applications of siRNA for Pfizer. He has also worked for Pharmacia and Upjohn.
Dr. Nugent earned his BS from Miami University and his Ph.D. in organic chemistry from the University of Rochester.
This person is not in any offices
Tetra Therapeutics
Tetra Therapeutics is a clinical-stage biotechnology company developing medicines for Alzheimer's Disease, Fragile X syndrome, Traumatic Brain Injury, major depression, and schizophrenia.